Trial · NCT06115681
Real-world Study of Dedifferentiated Liposarcoma Patients in China
NCT06115681, Completed, Boehringer Ingelheim; results first posted 2025-07-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Real-world Study of Dedifferentiated Liposarcoma Patients in China. Trials, record NCT06115681. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06115681
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Study of Dedifferentiated Liposarcoma Patients in China
- NCT number
- NCT06115681
- Status
- Completed
- Enrollment
- 1,390 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Dedifferentiated Liposarcoma
- First posted
- 2023-11-03
- Last updated
- 2025-07-10
- Results first posted
- 2025-07-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1: Overall Survival | Time from index date until the earliest record of death or end of the study period, up to 10 years. | Overall survival (OS) as an event for each patient in Cohort 1 was defined as the date of death minus the index date or the start day of each line of therapy (LOT). For patients with no record of death, OS was censored at the last activity date before the end of the study period. |
| Secondary | Cohort 1, Cohort 2: Survival After Initial Diagnosis | Time from initial diagnosis until the earliest record of death or end of the study period, up to 10 years. | Survival after initial diagnosis for each patient was defined as the date of death minus the date of initial diagnosis. For patients with no record of death, survival after initial diagnosis was censored at the last activity date before the end of the study period. |
| Secondary | Cohort 1, Cohort 2: Total Number of Treatment Lines | At index date and during follow-up, up to 10 years. | The total number of treatment lines in both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy. |
| Secondary | Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | Number of patients with first line (1L) therapy by treatment type for both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy. |
| Secondary | Cohort 1, Cohort 2: Second Line (2L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | Number of patients with second line (2L) therapy by treatment type for both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy. |
| Secondary | Cohort 1, Cohort 2: Third Line (3L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | Number of patients with third line (3L) therapy by treatment type for both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy. |
| Secondary | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy | At index date and during follow-up, up to 10 years | Number of patients who received treatments with drugs classified as concurrent steroid therapy for both cohorts is reported. |
| Secondary | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Immunosuppressant Therapy | At index date and during follow-up, up to 10 years | Number of patients who received treatments with drugs classified as concurrent immunosuppressant therapy for both cohorts is reported. |
| Secondary | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Hormone Replacement Therapy | At index date and during follow-up, up to 10 years | Number of patients who received treatments with drugs classified as hormone replacement therapy for both cohorts is reported. |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Cohort 1, Cohort 2: Survival After Initial Diagnosis | Time from initial diagnosis until the earliest record of death or end of the study period, up to 10 years. | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis. Only patients with an existing diagnosis date were included in this analysis. | months | MEDIAN |
| SECONDARY | Cohort 1, Cohort 2: Total Number of Treatment Lines | At index date and during follow-up, up to 10 years. | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and being age ≥18 years at initial diagnosis. | Count of treatment lines per patient | MEDIAN |
| SECONDARY | Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis. Only patients with non-missing data were included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1, Cohort 2: Second Line (2L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis. Only patients with non-missing data were included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1, Cohort 2: Third Line (3L) of Therapy by Treatment Type | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and being age ≥18 years at initial diagnosis. Only patients with non-missing data were included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Immunosuppressant Therapy | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and being age ≥18 years at initial diagnosis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Hormone Replacement Therapy | At index date and during follow-up, up to 10 years | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and being age ≥18 years at initial diagnosis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Cohort 1: Overall Survival | Time from index date until the earliest record of death or end of the study period, up to 10 years. | All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis. Only patients who received at least one line of systemic antineoplastic treatment by the end of cohort identification period were included in this analysis. | months | MEDIAN |
Source ClinicalTrials.gov
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1, Cohort 2: Survival After Initial Diagnosis | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 30.3 | 95% Confidence Interval 26.8 to 36.7 | months | |
| Cohort 1, Cohort 2: Survival After Initial Diagnosis | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 38.4 | 95% Confidence Interval 35.0 to 42.6 | months | |
| Cohort 1, Cohort 2: Total Number of Treatment Lines | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 1.0 | Inter-Quartile Range 1.0 to 2.0 | Count of treatment lines per patient | |
| Cohort 1, Cohort 2: Total Number of Treatment Lines | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Count of treatment lines per patient | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | Anthracycline-based regimens | 119 | Participants | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | Anthracycline-based regimens | 12 | Participants | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | Anlotinib-based regimens | 85 | Participants | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | Anlotinib-based regimens | 12 | Participants | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | Apatinib-based regimens | 15 | Participants | |
| Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | Apatinib-based regimens | 1 | Participants |
1 to 10 of 49Source ClinicalTrials.gov
See all 49 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 275 | |
| Overall Study | STARTED | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 1,115 | |
| Overall Study | COMPLETED | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 275 | |
| Overall Study | COMPLETED | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 1,115 | |
| Overall Study | NOT COMPLETED | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 0 | |
| Overall Study | NOT COMPLETED | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 175 | 275 |
| Total, all-cause mortality | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 423 | 1,106 |
| Total, other adverse events | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 0 | 0 |
| Total, other adverse events | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 0 | 0 |
| Total, serious adverse events | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | 0 | 0 |
| Total, serious adverse events | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Hormone Replacement Therapy | Trial comparisons |
DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Immunosuppressant Therapy | Trial comparisons |
| DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): deaths from any cause | Trial comparisons |
DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06115681
GET https://conductscience.org/api/trials/v1/NCT06115681/results?page=2